WA
DGX icon

Westfuller Advisors’s Quest Diagnostics DGX Stock Holding History

Westfuller Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$590 Buy
3
+1
+50% +$194 ﹤0.01% 705
2025
Q4 		$347 Sell
2
-24
-92% -$4.37K ﹤0.01% 741
2025
Q3 		$4.96K Buy
+26
New +$4.61K ﹤0.01% 538

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Westfuller Advisors's DGX Position: Q1 2026 in Review

Westfuller Advisors increased its Quest Diagnostics (DGX) stake by 50% in Q1 2026, buying an estimated $194 and bringing the position to 3 shares worth $590. The position accounts for ﹤0.01% of the portfolio, ranked #705.

Westfuller Advisors first reported a position in DGX in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.96K in Q3 2025. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Westfuller Advisors held 3 shares of Quest Diagnostics worth $590 as of Q1 2026.
  • Westfuller Advisors bought 1 Quest Diagnostics share in Q1 2026, an estimated $194.
  • Quest Diagnostics made up ﹤0.01% of Westfuller Advisors's portfolio in Q1 2026, its #705 holding.
  • Westfuller Advisors first reported a position in Quest Diagnostics in Q3 2025 and has held it in 3 quarters since.
  • Westfuller Advisors's Quest Diagnostics position peaked at $4.96K in Q3 2025.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Westfuller Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.